Moderna Reports 71% Registration in Coronavirus Vaccine Trial With a target of roughly 30,000 participants, the 71% enrollment in the analysis is up substantially from last week, when the company reported registration of 17,458 participants, or 58 percent of the targeted registration.
The week-over-week enrollment growth is particularly impressive considering Moderna has stated it's slowed registration slightly to be able to increase the amount of minorities that are enrolled in the study. People of different races may respond differently to some vaccines and drugs, so it is essential for the clinical trial to test the vaccine on a varied population. Pfizer's latest update on Monday said the duo had registered 20,006, or 66 percent of the similarly sized clinical trial. On Friday, Pfizer pointed out that 6,000 participants had received another dose of this vaccine.
Whilst completing enrollment in the clinical trials is vital for determining security, the pace of registration is actually more important for efficacy since the companies can not begin measuring whether the vaccine protects individuals until the booster shot is given a few weeks after the first shot. Participants registered early in the study will receive their second dose sooner and can help determine if the complete course of treatment helps prevent COVID-19 compared to two placebo shots.
The week-over-week enrollment growth is particularly impressive considering Moderna has stated it's slowed registration slightly to be able to increase the amount of minorities that are enrolled in the study. People of different races may respond differently to some vaccines and drugs, so it is essential for the clinical trial to test the vaccine on a varied population. Pfizer's latest update on Monday said the duo had registered 20,006, or 66 percent of the similarly sized clinical trial. On Friday, Pfizer pointed out that 6,000 participants had received another dose of this vaccine.
Whilst completing enrollment in the clinical trials is vital for determining security, the pace of registration is actually more important for efficacy since the companies can not begin measuring whether the vaccine protects individuals until the booster shot is given a few weeks after the first shot. Participants registered early in the study will receive their second dose sooner and can help determine if the complete course of treatment helps prevent COVID-19 compared to two placebo shots.